TB-500 Dosing Timeline in 2026: Loading Phase, Maintenance, and What Researchers Observe

The standard TB-500 research protocol runs 8–12 weeks total, divided into a higher-dose loading phase (4–6 weeks) and a reduced-frequency maintenance phase (4–6 weeks). Most protocols cluster loading doses between 2.5–5 mg subcutaneously, twice weekly, followed by a maintenance dose of 2.5 mg once weekly.

Loading Phase: First 4–6 Weeks

The loading phase exists to saturate systemic distribution. Unlike BPC-157 — explored in depth in our BPC-157 vs TB-500 recovery comparison — TB-500 is framed as a whole-body circulatory peptide rather than a locally targeted one, which is why milligram-range doses are used instead of microgram-range [8].

The most widely documented loading structure: 2.5 mg subcutaneous injection, twice weekly (Monday/Thursday), for 4–6 weeks, yielding 5 mg/week total [1]. For acute structural injuries, some protocols push to 5 mg twice weekly (10 mg/week) for the same duration [2][4]. Reconstitute lyophilized powder with 2 mL bacteriostatic water per 10 mg vial (5 mg/mL), inject into abdominal subcutaneous tissue, and store reconstituted vials refrigerated at 2–8°C [1].

Researchers sourcing research-grade TB-500 for these protocols can compare current vendor options at Marek Health, which lists purity documentation alongside product specs.

Maintenance Phase and What to Expect

After loading, the protocol drops to 2.5 mg once weekly for 4–8 weeks, or every two weeks for chronic-condition models [2][3]. The rationale: once actin-sequestering activity and angiogenic signaling are underway, less exogenous peptide is needed to sustain the process [8][14].

Observable research benchmarks from compiled protocols [4][5]:

• Days 1–7: Reduced local inflammation, improved tissue perfusion
• Weeks 1–2: Measurable improvement in range of motion
• Weeks 2–3: Reported pain reduction and functional recovery markers

For context on how animal-model data maps to these timelines week-by-week, see TB-500 healing timeline: what animal studies actually show.

It's worth noting the compound landscape here: research peptides like TB-500 occupy a different regulatory tier than FDA-approved therapeutics. Wegovy (semaglutide), approved after the STEP-1 trial published in NEJM, and Zepbound (tirzepatide), validated in SURMOUNT-1 also in NEJM, have full regulatory clearance for human use. TB-500 does not — it remains a research compound with no approved human therapeutic indication as of July 2026, though Phase 1 IV data on recombinant thymosin beta-4 (NL005) confirmed favorable acute tolerability across doses up to 25 µg/kg [10]. Research use of the compound is legal; human therapeutic use without physician oversight is not the same category.

One practical note on safety framing: because TB-500's mechanisms include pro-angiogenic signaling via HIF-1α pathways, most protocols explicitly exclude researchers with active or recent malignancy from participation [6][8]. This is the single most consistent contraindication across published protocol literature.

Researchers building or evaluating peptide stacks can review the full peptide therapy treatment hub for protocol comparisons across compounds.

---

Frequently asked questions

What is the standard TB-500 loading dose per week?

The standard TB-500 loading dose is 5 mg per week, typically split into two 2.5 mg subcutaneous injections administered on non-consecutive days across a 4–6 week period [1][2]. More aggressive acute-injury protocols use up to 10 mg per week (5 mg twice weekly), while weight-based calculations suggest 30–60 µg/kg per injection for an 80 kg subject [2][4].

How long does a full TB-500 research protocol run?

A complete TB-500 protocol typically runs 8–12 weeks total: 4–6 weeks of loading followed by 4–6 weeks of maintenance dosing [1][4]. Most researchers do not extend beyond 12 continuous weeks in a single cycle, partly due to cost and partly due to theoretical concerns around sustained pro-angiogenic activity [12][18].

Is TB-500 legal to purchase for research use?

TB-500 is legal to purchase as a research compound in the United States as of July 2026; it is not FDA-approved for human therapeutic use, and no approved indication exists. Researchers sourcing it for legitimate laboratory or investigational purposes operate in a distinct legal category from human therapeutic use. Vendors like those listed at NextGen Peptides supply research-grade material with third-party purity documentation.